A multicenter retrospective clinical study of a simplified comprehensive geriatric assessment system in elderly patients with diffuse large B-cell lymphoma
10.3760/cma.j.cn121090-20241121-00467
- VernacularTitle:简化老年综合评估在老年弥漫大B细胞淋巴瘤中应用的多中心回顾性临床研究
- Author:
Jiayan LENG
1
;
Yihong CAI
;
Xueping GE
;
Nanping ZHAO
;
Qianqian SU
;
Zhuxia JIA
;
Jun QIAN
;
Bingzong LI
;
Haiying HUA
;
Xuzhang LU
;
Huayuan ZHU
;
Jianyong LI
;
Wenyu SHI
Author Information
1. 江苏大学附属人民医院血液科，镇江 212002
- Publication Type:Journal Article
- Keywords:
Lymphoma, B cell;
Simplified, comprehensive geriatric assessment;
Survival analysis
- From:
Chinese Journal of Hematology
2025;46(2):126-133
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the predictive value of simplified geriatric assessment (sGA) in elderly Chinese patients diagnosed with diffuse large B-cell lymphoma (DLBCL) .Methods:It retrospectively analyzed the relationships of sGA with the clinical characteristics, outcome, and prognosis of 219 patients aged ≥60 years who were newly diagnosed with DLBCL at six hospitals in Jiangsu province between January 2018 and December 2022.Results:The median age of 219 patients was 68 years (60-87 years). According to the sGA system criteria, 101 (46.1%), 103 (47.0%), and 15 (6.8%) elderly patients with DLBCL were categorized as fit, unfit, and frail, respectively. The most common adverse reactions after chemotherapy were hematologic, and the incidence of grade >2 hematologic adverse reactions was similar among the three groups (47.5% vs 41.7% vs 46.7%, respectively; χ2=0.712, P=0.700). Compared with the fit and unfit groups, the frail group showed tendencies toward for higher proportions of grade >2 gastrointestinal, pulmonary, and infectious adverse reactions ( P>0.05 for all). The fit, unfit, and frail groups had respective remission rates of 74.3%, 46.6%, and 20.0% ( χ2=25.249, P<0.001) ; disease progression rates of 5.9%, 11.7%, and 26.7% ( χ2=6.763, P<0.05) ; 2-year overall survival rates of 92.1% (95% CI 86.6% to 97.9%), 77.6% (95% CI 69.5% to 86.6%), and 70.1% (95% CI 49.4% to 99.6%) ( P<0.05) ; and 2-year progression-free survival rates of 76.8% (95% CI 67.0% to 84.8%), 69.7% (95% CI 61.8% to 82.0%), and 65.7% (95% CI 53.3% to 100%) ( P=0.399) . Conclusion:sGA can effectively predict treatment adverse effects and efficacy, disease progression, and long-term survival in elderly DLBCL.
